Background. Tens of millions of seniors are at risk of herpes zoster (HZ) and its complications. Live attenuated herpes zoster vaccine (HZV) reduces that risk, although questions regarding effectiveness and durability of protection in routine clinical practice remain. We used Medicare data to investigate HZV effectiveness (VE) and its durability.
Herpes zoster (HZ) is a painful condition resulting from the reactivation of the varicella-zoster virus (VZV) from a latent state in sensory nerve ganglia. The disease manifests as a vesicular rash, characteristically unilateral, and restricted to a single dermatome, accompanied by pain along the dermatome. Older populations are particularly affected as the incidence and severity increases with age. There is a marked increase in the incidence of HZ after age 50, which correlates with aging-related decline in cell-mediated immunity [1] . Studies in Canada, Israel, Japan, Taiwan, and the United States reported age-adjusted HZ incidence rates of 8 to 11 per 1000 person-years in populations ages ≥65 years, whereas incidence in the general population was lower, ranging from 3.4 to 5.0 per 1000 person-years [2, 3] . Complications of HZ include ophthalmic zoster (OZ), bacterial superinfections of skin lesions and disseminated infections, particularly among immunocompromised patients [4] . The most common serious complication of HZ is postherpetic neuralgia (PHN) [5] . Adults older than 70 years have a 4-fold increased risk of PHN compared with those younger than 60 years [6, 7] .
The live-attenuated herpes zoster vaccine, ZOSTAVAX® (Zoster Vaccine Live; Merck & Co., Inc., Whitehouse Station, NJ) was initially licensed in the United States in 2006 to prevent HZ, following a clinical trial in over 38 000 participants ages ≥60 years with no history of HZ, immunosuppression, or other conditions that could interfere with study participation [8] . In this randomized study, the vaccine (HZV) reduced HZ incidence by 51% (95% CI: 44%, 58%) [1] . Post-marketing studies have generally not been powered to fully explore the roles and interactions of factors such as time since vaccination, age, and disease outcome (e.g., PHN, OZ, and hospitalized HZ) on HZV effectiveness [1, [9] [10] [11] [12] [13] [14] [15] .
Our objective in this study was to use Medicare databases to robustly evaluate the effectiveness and duration of protection provided by the live-attenuated HZV among beneficiaries ages ≥65 years by age and risk group.
METHODS

Study Population
Medicare beneficiaries ages ≥65 years enrolled in fee-forservice Medicare Parts A (inpatient services), B (outpatient services), and D (prescription drugs) were analyzed retrospectively, comparing those who received a claim for HZV to those who were unvaccinated. Exposure to the HZV was identified using National Drug Codes (NDCs) for ZOSTAVAX, with the vaccination date used as the index date. Vaccinations between January 1, 2007, and July 31, 2014 were eligible for use as index dates. For the unvaccinated cohort, index dates were assigned to match the distribution of vaccination dates, subject to eligibility requirements.
Beneficiaries were included in the analyses if they had 12 months of continuous enrollment in Medicare A/B/D, ensuring that data exist to define baseline characteristics (Figure 1) . Additionally, to ensure that unvaccinated beneficiaries were truly unvaccinated, beneficiaries were included in analyses only if they were enrolled in Medicare Part D since at least May 2006, when HZV was first licensed. Beneficiaries were excluded if they had an overlapping nursing home, skilled nursing facility, or hospice stay because claims from these settings are less complete, or if they received an HZ diagnosis or claim for an immunocompromising medical condition in the 12 months prior, or immunosuppressive treatment in the 6 months prior to their index date (Appendix I-II), because these conditions and drugs are known to reduce the effectiveness of the vaccine.
Cohort Follow-up
Start of follow-up began 30 days after cohort entry [1] . Beneficiaries were followed continuously until: a subsequent HZV claim, death, disenrollment from fee-for-service Medicare, end of study (July 31, 2014) , admission to a nursing home, skilled nursing facility, or hospice, occurrence of the outcome of interest, or an immunosuppressive drug claim in the first 2 months after index date.
Outcomes
Incident HZ cases were defined using International Classification of Diseases, Ninth Revision (ICD-9-CM) codes (053.XX for HZ and 053.2X for OZ). Cases were captured in institutional and noninstitutional care settings and categorized into 5 separate outcomes: community HZ, hospitalized HZ, community OZ, hospitalized OZ, and PHN. We do not present our hospitalized OZ results because of low sample size and overall similarity to findings on hospitalized HZ. To identify hospitalized HZ, we used inpatient claims with a primary diagnosis of HZ, which has been shown to have a positive predictive value (PPV) of 86% [15] . For community cases, outcomes in any diagnosis position were used with reported PPVs ranging from 85.2% to 98% [7, 16] .
PHN is an important consequence of HZ, especially in older adults. However, detection of PHN may be biased when ascertainment is restricted to medically attended care and is particularly challenging when using administrative data [10, 16] . PHN was defined using a modified version of the algorithm in Klompas et al. [16] . Cases of PHN were identified based on the presence of ICD-9 053.xx in the 90-180 days after an incident HZ diagnosis in combination with at least one of the following events: (1) a new prescription of a PHN treatment (Appendix III) in the 0-60 days from incident HZ diagnosis, (2) the presence of HZ with nervous system complications (ICD-9 053.1x) in the 90-180 days from incident HZ diagnosis, or (3) the presence of a new diagnosis for neuralgia (ICD-9 729.2x) in the 0-180 days from incident HZ diagnosis.
Covariates
This study accounted for well-studied risk factors of HZ in addition to other potential risk factors believed to be associated with risk of HZ or propensity to seek care once HZ is contracted (Appendix IV) [11, 14, 17, 18] . To achieve balance between cohorts, 1:1 propensity score matching was used, with propensity scores estimated from a logistic regression using all covariates. Beneficiaries were matched using this propensity score and the minimum Mahalanobis distance for key covariates: age, sex, race, and low-income subsidy status [19] .
Falsification Outcomes
HZV recipients might differ from nonrecipients in their ability or desire to access care for HZ or on other unmeasured confounders, introducing ascertainment or selection bias. We adopted the approach in Tseng et al. [11, 17, [20] [21] [22] [23] to check for such bias: hazard ratios were calculated for 13 acute symptomatic conditions (Appendix V) in the vaccinated and matched unvaccinated cohorts. Because these conditions were unrelated to HZ, as a group, the hazard ratios were expected to cluster around 1.0; any deviations from 1.0 would alert us to potential biases.
Statistical Analysis
Incident outcome rates were calculated by dividing the number of cases by the total person-years of observation. Doubly robust Cox regression models were used to estimate the hazard ratios for incident HZ and PHN in the vaccinated compared with the unvaccinated population, in which time intervals were interacted with vaccine status. Doubly robust models adjust for all baseline characteristics (Appendix IV) to account for any residual confounding in post-matching analyses [24, 25] . Additionally, for those beneficiaries in the cohorts who were started on immunosuppressive therapies after the index date, drug use was included in the model as a time-varying covariate (Appendix II). Vaccine effectiveness (VE) was calculated as (1−HR) × 100%, where HR is the estimated hazard ratio between the 2 cohorts for a particular time interval, unless noted otherwise.
The secondary analysis used analogous methods but compared HZ vaccinees to beneficiaries who received a pneumococcal vaccine (PV; Pneumovax®23, Merck & Co Inc., Whitehouse Station, New Jersey) but did not receive HZV. PV beneficiaries were followed from vaccination as their index date. Additional analyses were performed on both primary and The balance of covariates between the matched cohorts was assessed using the standardized mean difference [20] . A standardized mean difference of 0.1 or less indicated a negligible difference in means or proportions between cohorts.
c The age distribution corresponds to the eligibility restriction that required beneficiaries be enrolled in Medicare since vaccine licensure. Frailty characteristics consisted of dementia, home oxygen use, urinary catheter use, walker use, and wheelchair use. These characteristics were identified in 1%-4% of the base population, where each was balanced between vaccinated and unvaccinated cohorts.
The full list of covariates that were included in the propensity score model are provided in Appendix IV.
secondary populations to investigate whether there was effect modification due to age, sex, and race. This study was performed as part of the SafeRx Project, a joint initiative of the Centers for Medicare and Medicaid Services (CMS) and the US Food and Drug Administration (FDA). It was approved by the Research in Human Subjects Committee of FDA's Center for Biologics Evaluation and Research. Analyses were performed using R 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria) and SAS 9.4 (SAS Institute Inc., Cary, North Carolina).
RESULTS
Primary Analysis
Prior to matching, vaccinated and unvaccinated beneficiaries differed considerably. After matching, a total of 945 992 vaccinated and 945 992 unvaccinated beneficiaries were obtained, resulting in well-balanced cohorts ( Table 1 ). The population was 67% female, 90% white, and 77 years old on average at index date. Beneficiaries were followed for up to 7.5 years with the average length of follow-up being 2.5 years. Approximately 4% of beneficiaries were censored due to death and 17% due to admittance to a nursing home, skilled nursing facility, or hospice. During follow-up, 0.7% of eligible beneficiaries began immunosuppressive treatment.
A total of 56 964 incident zoster outcomes were detected in our matched study population. Among the 29 401 cases in the unvaccinated cohort, 29 383 (>99%) received community care, 429 (1%) were hospitalized, 2,699 (9%) experienced OZ, and 1,229 (4%) experienced PHN. In the unvaccinated, the incidence of HZ was 15.0 per 1000 person-years for community events and 0.21 per 1000 person-years for hospitalized events. About 4% of community and 9% of hospitalized cases were also coded as PHN ( Table 2 , eTable 1). HZ rates remained steady by calendar year in the unvaccinated cohort (eFigure 2).
Before conducting the main analysis, we assessed whether there were underlying differences between study cohorts. We compared vaccinated to unvaccinated beneficiaries using 13 falsification outcomes, which were expected to have no association with HZ. The adjusted hazard ratio (AHR) of the 13 falsification outcomes in the vaccinated and unvaccinated cohorts ranged from 0.72 (95%CI: 0.70-0.73) for hip fracture outcomes to 1.17 (95%CI: 1.15-1.20) for lipoma ( Figure 2) . After running the main analysis, none of the 13 outcomes had an AHR as far from the null (1.0) as that of the zoster outcomes. In the fully adjusted analysis, vaccination was associated with a reduced risk of HZ (Table 3a) . Compared to unvaccinated beneficiaries, in the first 3 years of follow-up, the adjusted vaccine effectiveness (AVE) was 33% (95% CI 32%-35%) for community HZ; AVE declined slightly by age (P = .029), where it was highest in ages 65-69 (36% [95% CI 33%-39%]) and lowest in ages 80-84 (31% [95% CI 28%-34%]). For hospitalized HZ and PHN, the AVE for the first 3 years of follow-up was higher: 74% (95% Cl: 67%-79%) and 57% (95% CI: 52%-61%), respectively. For all outcomes, there was no evidence of effect modification by gender. Key predictors of HZ by setting are displayed in eTable 2.
For community HZ, AVE declined significantly over time (Table 3a) . VE was not only higher but also better retained over time for PHN and hospitalized HZ than for community HZ. Trends on the duration of protection for the vaccine are also summarized in Figure 2 . The unadjusted hazard rate for unvaccinated beneficiaries was flat in outcomes over time, whereas the vaccinated started off with a low HZ hazard that increased over time.
Secondary Analysis
In the secondary analyses, we matched 608 982 HZV recipients to 608 982 recipients of pneumococcal vaccine (Table 3c ; Supplemental Material). The AVE in the first 3 years of follow-up for community HZ (37%, 95% CI 36%-39%) was 4% higher than for the primary analysis (Table 3c) . Results for all other outcomes, including HZ hospitalizations and PHN, were similar to those in the primary analysis.
DISCUSSION
We used matched cohort data from approximately 2 million Medicare beneficiaries to investigate HZ vaccine effectiveness and duration of protection, using multiple analytical approaches to identify and address potential bias. This study assesses the -3% (-92%, 45%) 44%** (29%, 56%) 26%* (4%, 43%) 49%** (25%, 66%) 28% (-8%, 52%) Other 24%** (15%, 33%) 6% (-6%, 17%)
Abbreviations: CI, confidence interval; HR, hazard ratio; HZ, herpes zoster; VE, vaccine effectiveness. a Significance: ** P < .01, * P < .05. effectiveness and durability of the live-attenuated HZV with sufficient power to examine less common outcomes such as PHN and HZ-associated hospitalizations, while controlling for a wide range of HZ risk factors and potential confounders [1, 9, 12, 26, 27] . Furthermore, our Medicare fee-for-service data are sourced from the general US population ages 65 years and older, capturing the entire range of routine clinical practice.
Among eligible study participants averaging 77 years of age, the primary and secondary analyses, respectively, found that HZV was 33% and 37% effective for the prevention of community HZ during the first 3 years postvaccination. For PHN and HZ-associated hospitalization, we found higher HZV effectiveness, 57% and 74%, respectively, for the first 3 years postvaccination in the primary analysis. The differences in these estimates, and their consistency in both the primary and secondary analyses, suggest real differences in VE for each of these endpoints. The higher VE for PHN (57%) than for community HZ (33%) suggests some incremental benefit of the vaccine in prevention of PHN beyond prevention of HZ per se; this is also suggested by the higher proportion of HZ cases who had PHN, a complication of HZ, among unvaccinated relative to vaccinated cohorts (4.0% vs 2.9%, respectively).
These results were consistent for the primary and secondary analyses; nonetheless, the different estimates could also, in part, reflect the influence of differences in ascertainment, or other potential biases that could have differentially influenced detection of each endpoint in vaccinated versus unvaccinated beneficiaries.
Although the Shingles Prevention Study reported declines in VE with age, our study found only limited evidence of age-related declines in VE, which is a pattern previously reported [1, 11] . The difference with the SPS may relate to case finding: HZ severity increases with age [1] . HZ severity would be less likely to affect case finding in the SPS clinical trial with its active phone-based surveillance, but it would in medical sector-based studies such as ours. Although our results showed a small decline in VE for community HZ between age groups, there was no evidence of decline in other outcomes, which indicates that VE does not change substantially with increasing age. HZV also appears to protect Medicare beneficiaries despite their high burden of chronic illness. Overall, our VE results are consistent with those of other studies, although point estimates vary across studies due to differences in source population characteristics, case definitions and ascertainment, and other aspects of study methodology [11, 12] . In our study, as in other observational studies, the overall vaccine effectiveness estimates may be less accurate than relative VE estimates based on internally controlled comparisons (such as age-specific and time-specific changes in vaccine effectiveness).
In both the primary and secondary analyses, VE for community HZ declined significantly for years 4+ postvaccination to 19% and 22%, respectively, showing that HZV protection declines over time. Similar results have been published based on long-term follow-up of the original study cohort from the SPS, but the long-term follow-up study was uncontrolled and unblinded [12] . A recent prospective cohort study also showed waning of protection, though that study, conducted at a large health maintenance organization [27] , had less analytic power and generalizability than our study. For PHN and HZ-associated hospitalization, protection was better preserved than for community HZ with AVEs of 45% and 55%, respectively, for years 4+ in the primary analysis. The differences found in duration of protection would need to be investigated further in other studies.
This study has several limitations. Because Medicare is an administrative database, outcomes and risk factors were not verified by medical record review. However, previous record validation studies have consistently shown relatively high positive predictive value for HZ as an outcome [11, [28] [29] [30] . Additionally, published population-based studies have indicated that over 90% of adults self-reporting HZ sought medical attention for the condition [31] [32] [33] [34] . If measurement error were a problem, we would expect VE for nonspecific outcomes like community HZ to be understated. However, when we analyzed OZ, which is a particularly distressing form of HZ that would almost certainly require medical attention, we found that HZV was similarly effective at preventing community OZ as it was for preventing community HZ. In general, analyzing more specific outcomes in observational studies may sometimes introduce biases by focusing on particular segments of the population. For example, HZ-attributable hospitalization is an imperfect surrogate for HZ disease severity, as even primary-HZ coded hospitalizations are not always attributable to HZ [15] . The rates of HZ-associated hospitalization may be influenced by other risk factors for hospitalization not directly due to HZ. In an effort to address this limitation we explored a more specific outcome with an analysis that restricted community HZ to cases receiving antiviral treatment, and found that estimated VE was only modestly increased (eTable 6).
We believe that this study is unlikely to have much error in measuring vaccination status. Our cohorts are restricted to beneficiaries enrolled in Medicare from the time HZV was licensed so that any HZV would very likely be recorded in Medicare claims. It is also unlikely that many Medicare beneficiaries would choose to pay for this vaccine out-of-pocket, so Medicare claims are likely to be nearly complete for this population. However, because we used a conservative continuous-enrollment criteria, the average age of our cohorts was older than that for Medicare as a whole; thus, VE estimates in our study populations might have been lower than for the general Medicare population.
Vaccinees may differ from nonvaccinees with respect to both disease risk and healthcare-seeking behavior. Community HZ, in particular, can be missed among beneficiaries who tend to forgo medical care for nonserious conditions. To ensure comparability between cohorts, we matched by multiple potential confounders and conducted a vaccinee-vaccinee analysis as a secondary analysis. Falsification outcomes provide a novel supplementary approach for identifying bias. Our falsification outcomes clustered around the null (1.0), suggesting that there was no systemic bias influencing relative outcomes in vaccinees versus controls. Our aggregate use of this large number of falsification outcomes was intended to provide a more robust comparison group, under the expectation that it is unlikely that all these independently-selected conditions would share causal pathways with HZ. Nonetheless, examination of the results of the individual conditions and their variance can provide clues with which to detect and better understand residual differences between vaccine and control groups.
In the secondary analysis, VE for community HZ in the first 3 years postvaccination was only slightly higher than in the primary analysis (37% vs 33%) and was similar to the primary analysis for all other outcomes. This suggests that any potential bias related to healthcare-seeking behavior is minimal. Indeed, although falsification outcomes did cluster more tightly around the null in the secondary analysis compared with the primary, the difference was slight. The 67% VE estimate for HZ-associated hospitalizations for the first 3 years postvaccination in the secondary analysis was only 7% lower than in the primary analysis, and differences in VE for HZ-associated hospitalizations were not statistically significant (Table 3b ). Further research would be needed to confirm this.
In summary, we observed that the duration of protection against community HZ wanes over time, yet the vaccine protects against HZ regardless of age and chronic illness. We calculated that the number needed to vaccinate to avert an episode of community HZ during our study period was just 30.6 (eTable 8). Our findings provide additional evidence that the live HZV is effective at reducing the incidence of HZ and its complications when used in clinical practice among Medicare beneficiaries. Although effectiveness against community HZ was not high, the protection provided by this vaccine was higher and more durable for HZ-hospitalizations and PHN.
